

This poster is part of the Risk Management Plan of Perfalgan® to minimize the risk of overdose.

- The volume of Perfalgan® 10 mg/mL administered should never exceed 75 mL per dose.
- The dose in these patients is 15 mg/kg. The maximum daily dose in these patients should not exceed 3 g in 24 hours.
- The dose in these patients is 15 mg/kg. The maximum daily dose in these patients should not exceed 3 g in 24 hours.

For children, adolescents and adults weighing > 33 kg but ≤ 50 kg:

- The dose in these patients is 7.5 mg/kg.
- The volume of Perfalgan® 10 mg/mL administered should never exceed 7.5 mL per dose in this weight group. Smaller volumes will be required with lower weights.
- The Perfalgan® glass vial should not be hung as an infusion due to the small volume of the medicinal product to be administered in this population.
- A 5 mL or 10 mL syringe should be used to measure the dose as appropriate for the weight of the child and the desired volume.
- The volume to be administered should be withdrawn from the vial and could be administered undiluted or diluted (from one to nine volumes diluent) in a 0.9% sodium chloride solution or 5% glucose solution and administered in 15 minutes.

For children weighing ≤ 10 kg:

SOLUTION FOR INFUSION

Perfalgan®
paracetamol
10 mg/mL

SOLUTION FOR INFUSION

Short-term treatment of moderate pain, especially following surgery and for the short-term treatment of fever, when administration by intravenous route is clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible. ⁽¹⁾

DOSING TOOL

Administration protocol. Dosing table for Perfalgan® 10 mg/mL ⁽¹⁾

Patient weight	Dose per administration	Volume per administration	Maximum volume per administration based on upper weight limits of group (mL)*	Maximum daily dose
≤ 10 kg	7.5 mg/kg	0.75 mL/kg	7.5 mL	30 mg/kg
> 10 kg to ≤ 33 kg	15 mg/kg	1.5 mL/kg	49.5 mL	60 mg/kg not exceeding 2 g
> 33 kg to ≤ 50 kg	15 mg/kg	1.5 mL/kg	75 mL	60 mg/kg not exceeding 3 g
> 50 kg with additional risk factors for hepatotoxicity	1 g	100 mL	100 mL	3 g
> 50 kg and no additional risk factors for hepatotoxicity	1 g	100 mL	100 mL	4 g

* Patients weighing less require smaller volumes.

The minimum interval between each administration must be at least 4 hours. No more than 4 doses to be given in 24 hours. The minimum interval between each administration in patients with severe renal insufficiency must be at least 6 hours.

(1) Summary of Product Characteristics of Perfalgan® 10 mg/mL, solution for infusion.

10 mg = 1 mL

Quantity of Perfalgan®
mg
Volume of Perfalgan®
mL
Patient weight
kg

Perfalgan®

paracetamol 10 mg/mL

SOLUTION FOR INFUSION

The minimum interval between each administration must be at least 4 hours. No more than 4 doses to be given in 24 hours.

The minimum interval between each administration in patients with severe renal insufficiency must be at least 6 hours.

mg - Quantity of Perfalgan®		ml - Volume of Perfalgan®		kg - Patient weight	
750	75	49.5	33	50	1
735	73.5	48	32	49	2
720	72	46.5	31	48	3
705	70.5	45	30	47	4
690	69	43.5	29	46	5
675	67.5	42	28	45	6
660	66	40.5	27	44	7
645	64.5	39	26	43	8
630	63	37.5	25	42	9
615	61.5	36	24	41	10
600	60	34.5	23	40	11
585	58.5	33	22	39	12
570	57	31.5	21	38	13
555	55.5	30	20	37	14
540	54	28.5	19	36	15
525	52.5	27	18	35	16
510	51	25.5	17	34	17
495	49.5	24	16	33	18
480	48	22.5	15	32	19
465	46.5	21	14	31	20
450	45	19.5	13	30	21
435	43.5	18	12	29	22
420	42	16.5	11	28	23
405	40.5	15	10	27	24
390	39	14	9	26	25
375	37.5	13	8	25	26
360	36	12	7	24	27
345	34.5	11	6	23	28
330	33	10	5	22	29
315	31.5	9	4	21	30
300	30	8	3	20	31
285	28.5	7	2	19	32
270	27	6	1	18	33
255	25.5	5.5		17	34
240	24	5.2		16	35
225	22.5	4.5		15	36
210	21	3.7		14	37
195	19.5	3		13	38
180	18	2.2		12	39
165	16.5	1.5		11	40
75	7.5	0.75		10	41
67	6.7			9	42
60	6			8	43
52	5.2			7	44
45	4.5			6	45
37	3.7			5	46
30	3			4	47
22	2.2			3	48
15	1.5			2	49
7.5	0.75			1	50

Short-term treatment of moderate pain, especially following surgery and for the short-term treatment of fever, when administration by intravenous route is clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible. ⁽¹⁾

(1) Summary of Product Characteristics of Perfalgan® 10 mg/mL, solution for infusion.



Pull